Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma

Stem Cells

Volumn 26, Issue 3, 2008, Pages 831-841

  Sonabend, Adam M ^a   Ulasov, Ilya V ^a   Tyler, Matthew A ^a   Rivera, Angel A ^b   Mathis, James M ^c   Lesniak, Maciej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b University of Alabama at Birmingham   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Adenovirus; Gene therapy; Glioma; Migration; Oncolytic virus; Stem cells; Vector

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CHEMOKINE RECEPTOR CXCR4; E1A PROTEIN; LUCIFERASE; ONCOLYTIC ADENOVIRUS;

ADENOVIRUS; ADENOVIRUS 3; ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CANCER MODEL; CELL MEMBRANE; DRUG DELIVERY SYSTEM; GLIOBLASTOMA; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; POLYMERASE CHAIN REACTION; PROMOTER REGION; TUMOR XENOGRAFT; ANIMAL; BRAIN TUMOR; CANCER TRANSPLANTATION; CELL MOTION; CYTOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSDUCTION; GENETICS; GLIOMA; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; VIRUS REPLICATION;

ADENOVIRIDAE; MUS;

ADENOVIRIDAE; ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION REGULATION; GLIOMA; HUMANS; MALE; MESENCHYMAL STEM CELLS; MICE; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIROTHERAPY; PROMOTER REGIONS (GENETICS); RECEPTORS, CXCR4; TRANSDUCTION, GENETIC; VIRUS REPLICATION;

EID: 43049095411     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2007-0758     Document Type: Article

References (41)

1. Annegers JF, Schoenberg BS, Okazaki H et al. Epidemiologic study of primary intracranial neoplasms. Arch Neurol 1981;38:217-219.
2. Louis DN, Holland EC, Cairncross JG. Glioma classification: A molecular reappraisal. Am J Pathol 2001;159:779-786.
3. Ehtesham M, Stevenson CB, Thompson RC. Stem cell therapies for malignant glioma. Neurosurg Focus 2005;19:E5.
4. Ichikawa T, Chiocca EA. Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector. Cancer Res 2001;61:5336-5339.
5. Chiocca EA, Abbed KM, Tatter S et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004;10:958-966.
6. Tyler MA, Ulasov IV, Borovjagin A et al. Enhanced transduction of malignant glioma with a double targeted Ad5/3-RGD fiber-modified adenovirus. Mol Cancer Ther 2006;5:2408-2416.
7. Sonabend AM, Ulasov IV, Lesniak MS. Conditionally replicative adenoviral vectors for malignant glioma. Rev Med Virol 2006;16:99-115.
8. Zhu ZB, Makhija SK, Lu B et al. Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo. Int J Oncol 2005;27:237-246.
9. Sandmair AM, Loimas S, Puranen P et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000;11:2197-2205.
10. Lichtenstein DL, Wold WS. Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: Replication, safety, and transmission. Cancer Gene Ther 2004;11:819-829.
11. Lang FF, Bruner JM, Fuller GN et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results. J Clin Oncol 2003;21:2508-2518.
12. Ehtesham M, Kabos P, Kabosova A et al. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res 2002;62:5657-5663.
13. Ehtesham M, Yuan X, Kabos P et al. Glioma tropic neural stem cells consist of astrocytic precursors and their migratory capacity is mediated by CXCR4. Neoplasia 2004;6:287-293.
14. Lesniak MS. Targeted therapy for malignant glioma: Neural stem cells. Expert Rev Neurother 2006;6:1-3.
15. Serfozo P, Schlarman MS, Pierret C et al. Selective migration of neuralized embryonic stem cells to stem cell factor and media conditioned by glioma cell lines. Cancer Cell Int 2006;6:1.
16. Ziu M, Schmidt NO, Cargioli TG et al. Glioma-produced extracellular matrix influences brain tumor tropism of human neural stem cells. J Neurooncol 2006;79:125-133.
17. Nakamizo A, Marini F, Amano T et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005;65:3307-3318.
18. Nakamura K, Ito Y, Kawano Y et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004;11:1155-1164.
19. Friedenstein AJ, Chailakhyan RK, Gerasimov UV. Bone marrow osteogenic stem cells: In vitro cultivation and transplantation in diffusion chambers. Cell Tissue Kinet 1987;20:263-272.
20. Bianco P, Riminucci M, Gronthos S et al. Bone marrow stromal stem cells: Nature, biology, and potential applications. STEM CELLS 2001;19:180-192.
21. Conget PA, Minguell JJ. Adenoviral-mediated gene transfer into ex vivo expanded human bone marrow mesenchymal progenitor cells. Exp Hematol 2000;28:382-390.
22. Stoff-Khalili MA, Rivera AA, Mathis JM et al. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat 2007;105:157-167.
23. Komarova S, Kawakami Y, Stoff-Khalili MA et al. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006;5:755-766.
24. Lopez Ponte A, Marais E, Gallay N et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: Comparison of chemokine and growth factor chemotactic activities. STEM CELLS 2007;25:1737-1745.
25. Son BR, Marquez-Curtis LA, Kucia M et al. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. STEM CELLS 2006;24:1254-1264.
26. Ulasov IV, Rivera AA, Sonabend AM et al. Comparative evaluation of survivin, midkine, and CXCR4 promoters for transcriptional targeting of glioma gene therapy. Cancer Biol Ther 2007;6:679-685.
27. Zheng S, Ulasov IV, Han Y et al. Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma. J Gene Med 2007;9:151-160.
28. Van Houdt WJ, Haviv YS, Lu B et al. The human survivin promoter: A novel transcriptional targeting strategy for treatment of glioma. J Neurosurg 2006;104:583-592.
29. Ulasov IV, Tyler MA, Zheng S et al. CD46 represents a target for adenoviral gene therapy of malignant glioma. Hum Gene Ther 2006;17:556-564.
30. Ulasov IV, Zhu ZB, Tyler MA et al. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther 2007;18:589-602.
31. Tekant Y, Davydova J, Ramirez PJ et al. Oncolytic adenoviral therapy in gallbladder carcinoma. Surgery 2005;137:527-535.
32. Majem M, Cascallo M, Bayo-Puxam N et al. Control of E1a under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-Delta 24RGD. Cancer Gene Ther 2006;13:696-705.
33. Zhu ZB, Rivera AA, Makhija SK et al. Targeting lung cancer using an infectivity enhanced CXCR4-CRAd. Lung Cancer 2007;55:145-156.
34. Banerjee NS, Rivera AA, Wang M et al. Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures. Mol Cancer Ther 2004;3:437-449.
35. Zimmermann B, El-Sheikhah A, Nicolaides K et al. Optimized real-time quantitative PCR measurement of male fetal DNA in maternal plasma. Clin Chem 2005;51:1598-1604.
36. Suzuki K, Fueyo J, Krasnykh V et al. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001;7:120-126.
37. Short JJ, Pereboev AV, Kawakami Y et al. Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology 2004;322:349-359.
38. Honczarenko M, Le Y, Swierkowski M et al. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. STEM CELLS 2006;24:1030-1041.
39. Lee RH, Kim B, Choi I et al. Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue. Cell Physiol Biochem 2004;14:311-324.
40. Knaän-Shanzer S, van de Watering MJ, van der Velde I et al. Endowing human adenovirus serotype 5 vectors with fiber domains of species B greatly enhances gene transfer into human mesenchymal stem cells. STEM CELLS 2005;23:1598-1607.
41. Sordi V, Malosio ML, Marchesi F et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005;106:419-427.